Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Published:2016-08-30 Issue:1 Volume:7 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Wallin Jeffrey J.,Bendell Johanna C.,Funke Roel,Sznol Mario,Korski Konstanty,Jones Suzanne,Hernandez Genevive,Mier James,He Xian,Hodi F. Stephen,Denker Mitchell,Leveque Vincent,Cañamero Marta,Babitski Galina,Koeppen Hartmut,Ziai James,Sharma Neeraj,Gaire Fabien,Chen Daniel S.,Waterkamp Daniel,Hegde Priti S.,McDermott David F.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms12624.pdf

Reference28 articles.

1. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).

2. Latchman, Y. E. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101, 10691–10696 (2004).

3. Akbari, O. et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 3, 81–91 (2010).

4. Matsumoto, K. et al. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem. Biophys. Res. Commun. 365, 170–175 (2008).

5. McDermott, D. F. et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. 34, 833–842 (2016).

Cited by 580 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Firing up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration;Biomedicine & Pharmacotherapy;2024-10

3. Camrelizumab Combined with Transcatheter Arterial Chemoembolization for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis;Clinics and Research in Hepatology and Gastroenterology;2024-09

4. Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis;Frontiers in Oncology;2024-08-22

5. Real-world status, efficacy and prognosis analysis of first-line treatment for unresectable hepatocellular carcinoma in patients treated at multiple centres;Annals of Medicine;2024-08-21